Akili, the company behind video game-like prescription and over-the-counter digital therapeutics for individuals with ADHD, has signed a definitive merger agreement with mental health and fitness company Virtual Therapeutics in a deal reportedly worth $34 million.
Under the agreement, which is slated to close in the third quarter of 2024, Akili shareholders will receive $0.4340 per share of...
Akili, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported a rise in third-quarter revenue to $702,000, from $114,000 in the second quarter of this year, which the company attributes to the continued growth of its adult ADHD offering EndeavorOTC.
The company reported total operating expenses of $18.8 million for the third quarter, compared to $15...
Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its second-quarter earnings since expanding into the adult ADHD market in June with the release of its over-the-counter offering EndeavorOTC.
The Boston-based company reported $114,000 in revenue for the second quarter of 2023 compared to $113,000 in the first quarter of this...
Telehealth and medical transportation company DocGo saw its shares rise after reporting its first quarter financial results, showing total revenue of $113 million with a net loss of $3.9 million.
The company reported a 19% decline in mobile health revenue from $90.1 million in the first quarter of 2022 to $72.9 million in the first quarter of 2023 but a 44% increase in transportation services...
Global healthcare company AmerisourceBergen has announced a strategic partnership with business-to-business telehealth provider SteadyMD, beginning with the companies cocreating and piloting a telehealth offering for independent community pharmacies dubbed Test to Treat.
The Test to Treat model allows individuals to be tested for an illness or condition at an independent pharmacy and then consult...
Akili Interactive, the company behind a video game-like prescription digital therapeutic for children with ADHD, reported its first full-year earnings since going public last year.
The company reported $323,000 in revenue for 2022 compared with $538,000 for 2021. Akili said 2022 revenue was entirely made up of funds earned from sales of EndeavorRx, its therapeutic that received FDA clearance for...
Akili Interactive, maker of a video game-like digital therapeutic for children with ADHD, announced last week it will cut about 30% of its staff.
The layoffs, which will affect 46 workers, are expected to be completed by the end of the first quarter, according to a filing with the Securities and Exchange Commission.
Akili will also put some programs related to cognitive health outside of ADHD on...
Multinational digital health firm Babylon reported its third quarter revenue had grown to $288.9 million, a 3.9x year-over-year boost, thanks to an increase in its value-based care business primarily driven by growth in Medicare membership.
Babylon reported a loss of $89.9 million for the period, compared to a $66 million loss in Q3 2021. Adjusted earnings before interest, taxes, depreciation and...
Akili Interactive hit the public markets in August, bringing in cash the company will use to launch its video game digital therapeutic for children with ADHD later this year.
Akili's product, dubbed EndeavorRx, is prescription software for kids ages 8 to 12 who have attention issues. It received FDA De Novo clearance in 2020 after years waiting for the agency green light, though a nonprescription...
Akili, maker of a video game-like digital therapeutic for children with ADHD, hit the public markets Monday after wrapping up a merger with special-purpose acquisition company Social Capital Suvretta Holdings Corp. I.
The newly public digital health firm said the deal brought in more than $163 million before paying transaction expenses and advisory fees. Akili plans to use the cash to launch...
